2022
d-Limonene inhibits the occurrence and progression of LUAD through suppressing lipid droplet accumulation induced by PM2.5 exposure in vivo and in vitro
Zhu T, Li Y, Feng T, Yang Y, Zhang K, Gao J, Quan X, Qian Y, Yu H, Qian B. d-Limonene inhibits the occurrence and progression of LUAD through suppressing lipid droplet accumulation induced by PM2.5 exposure in vivo and in vitro. Respiratory Research 2022, 23: 338. PMID: 36496421, PMCID: PMC9741803, DOI: 10.1186/s12931-022-02270-9.Peer-Reviewed Original ResearchConceptsLipid droplet accumulationHuman intervention trialsLung cancer patientsLung adenocarcinomaPM2.5 exposureProgression of LUADDroplet accumulationPulmonary fibrosisIntervention trialsCancer patientsMiR-195Trichrome stainingChinese Clinical Trial RegistrySerum miR-195Clinical Trials RegistryLipid metabolism disordersNormal lung epithelial cellsPotential preventive interventionsNormal lung tissuesDe novo lipogenesis pathwayMasson's trichrome stainingDevelopment of LUADOil red stainingLung epithelial cellsPotential intervention targets
2016
Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer
Yu H, Irwin M. Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer. Energy Balance And Cancer 2016, 11: 251-264. DOI: 10.1007/978-3-319-41610-6_11.Peer-Reviewed Original ResearchDNA methylationTumor suppressor genePhysical activityEpigenetic regulationSuppressor geneCancer riskGenome-wide methylationBetter patient survivalBreast cancer patientsPro-inflammatory cytokinesBreast cancer riskSex steroid hormonesLower cancer riskMitogenic growth factorsEntire genomeMolecular mechanismsInsulin resistancePatient survivalCancer patientsMethylationMore profound impactsCancer preventionBreast cancerDisease outcomeHealthy individuals
2011
Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women
Qian B, Zheng H, Yu H, Chen K. Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research And Treatment 2011, 130: 217. PMID: 21562710, DOI: 10.1007/s10549-011-1552-9.Peer-Reviewed Original ResearchConceptsBreast cancer riskIGFBP-3 genotypesIGFBP-3 single nucleotide polymorphismsCancer riskChinese womenIGFBP-3Single nucleotide polymorphismsBreast cancerBreast tumorsTumor samplesLocal breast tissuesBreast cancer patientsIGF-I activityER-negative tumorsUnconditional logistic regressionCase-control studyFresh tumor samplesAge-matched controlsWilcoxon rank sum testRank sum testHigher peptide levelsIGFBP-3 geneIGF-I geneNegative tumorsCancer patients
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patients
2007
ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
Smith S, Su D, de la Longrais I, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. Journal Of Clinical Oncology 2007, 25: 5172-5179. PMID: 18024864, DOI: 10.1200/jco.2007.11.8547.Peer-Reviewed Original ResearchConceptsExcision repair cross-complementation group 1High ERCC1 expressionOvarian cancer patientsERCC1 expressionC genotypeDisease progressionGreater riskCancer patientsTreatment responseCodon 118Postoperative platinum-based chemotherapyEpithelial ovarian cancer patientsLow ERCC1 expressionSurvival of patientsPlatinum-based chemotherapyEpithelial ovarian cancerERCC1 mRNA expressionCombination of platinumERCC1 genotypePlatinum chemotherapyPoor prognosisOvarian cancerPaclitaxel treatmentGroup 1T genotypeIGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk
2006
High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer
Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson L, DeBenedetti A, Abreo F, Turnage R, McDonald J, Li B. High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer. Annals Of Surgery 2006, 243: 684-692. PMID: 16633004, PMCID: PMC1570543, DOI: 10.1097/01.sla.0000216770.23642.d8.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorCancer-related deathWorse clinical outcomesBreast cancer patientsHigh eIF4E overexpressionMicrovessel densityEIF4E overexpressionCancer specimensHigh eIF4ENodal statusClinical outcomesVEGF elevationMVD countCancer patientsCancer recurrenceBreast cancerStage IShorter disease-free survivalClinical surveillance protocolLow eIF4E overexpressionDisease-free survivalHighest cancer-related deathsHigher VEGF levelsTumor microvessel densityBreast cancer specimensUpregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients
Wolfort R, Chu Q, Turnage R, Yu H, Nuthalapaty S, De Benedetti A, Li B. Upregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients. Journal Of Surgical Research 2006, 130: 218-219. DOI: 10.1016/j.jss.2005.11.161.Peer-Reviewed Original ResearchMethylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic markerMethylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210. DOI: 10.1136/ijgc-00009577-200601000-00034.Peer-Reviewed Original ResearchIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2004
IGF‐I and breast cancer: A meta‐analysis
Shi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceIGFBP-3 levelsLevels of IGFIGF-binding proteinsBreast cancer riskStandardized mean differencePremenopausal womenBreast cancerIGFBP-3Cancer riskBreast cancer patientsEffects of IGFPostmenopausal womenPostmenopausal groupPremenopausal groupHigher IGFCancer patientsClinical studiesEpidemiologic studiesParacrine mechanismsIGFOverall associationMean differenceCancerWomenGenetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.
Ren Z, Cai Q, Shu X, Cai H, Li C, Yu H, Gao Y, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 1290-5. PMID: 15298948, DOI: 10.1158/1055-9965.1290.13.8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionBase SequenceBiomarkers, TumorBreast NeoplasmsCase-Control StudiesChinaConfidence IntervalsFemaleGenetic Predisposition to DiseaseHumansIncidenceInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsMiddle AgedMolecular Sequence DataOdds RatioPolymerase Chain ReactionPolymorphism, GeneticPopulation SurveillanceReference ValuesRisk AssessmentConceptsInsulin-like growth factorIGFBP-3 protein levelsBreast cancer riskBreast cancerVariant allelesIGFBP3 polymorphismsIGFBP-3IGFBP3 geneCancer riskElevated riskRisk genotypesActions of IGFsIncident breast cancer patientsChinese womenIGFBP-3 levelsIGF binding proteinBreast cancer patientsGenetic polymorphismsIGFBP-3 proteinProtein levelsCase-control studyDose-response mannerCancer patientsOdds ratioPolymorphism A
2001
Polymorphic CA repeats in the IGF-I gene and breast cancer
Yu H, Li B, Smith M, Shi R, Berkel H, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Research And Treatment 2001, 70: 117-122. PMID: 11768601, DOI: 10.1023/a:1012947027213.Peer-Reviewed Original ResearchConceptsBreast cancer patientsBreast cancerIGF-I geneCancer patientsCA repeatsUnconditional logistic regression analysisInsulin-like growth factorRole of IGFHigher odds ratioLogistic regression analysisHigher plasma IGFIGF-I genotypeBreast cancer cellsIGF-I polymorphismMenopausal statusPeripheral bloodPlasma IGFOdds ratioMedian numberNumber of CaCancerLarger studyAlcohol usePotent mitogenIGFInsulin-like growth factor-I and prostate cancer: a meta-analysis
Shi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceLevels of IGFProstate cancer patientsStandardized mean differenceIGFBP-3Prostate cancerHigher IGFCancer patientsInsulin-like growth factorIGF-binding proteinsEffects of IGFCase-control studyLow IGFMEDLINE searchIGFMean differenceGrowth factorCancerPatientsStandard protocolRiskLevelsFree insulin‐like growth factor‐I and breast cancer risk
Li B, Khosravi M, Berkel H, Diamandi A, Dayton M, Smith M, Yu H. Free insulin‐like growth factor‐I and breast cancer risk. International Journal Of Cancer 2001, 91: 736-739. PMID: 11267989, DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1111>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsIGF-I receptorInsulin-like growth factorFree IGFIGFBP-3Action of IGFBreast cancer patientsTotal IGFBreast cancer riskBreast cancerIGF-IICancer patientsPlasma levelsCancer riskFree insulin-like growth factorRace-matched healthy controlsFree IGF-I levelsConditional logistic regression analysisGrowth factorIGF-I levelsIGF binding proteinBinding of IGFHigher plasma levelsLogistic regression analysisHigher plasma IGFAnti-apoptotic effectsLevels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCase-Control StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualProstate-Specific AntigenProstatic NeoplasmsConceptsPostoperative serum samplesInsulin-like growth factor IIGFBP-3IGFBP-2Growth factor IProstate cancerSerum levelsSerum samplesFactor IIGFBP-2 levelsIGFBP-3 levelsIGF-I levelsGroup of patientsLow serum levelsProstate cancer patientsProstate cancer recurrenceProtein 2Recurrent diseaseDisease recurrenceMedian timePrognostic valueCancer patientsRadical prostatectomyCancer recurrenceSerum collection
2000
Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk
Wu X, Yu H, Amos C, Hong W, Spitz M. Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk. Journal Of The National Cancer Institute 2000, 92: 737-743. PMID: 10793110, DOI: 10.1093/jnci/92.9.737.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideBleomycinCase-Control StudiesChromosome AberrationsData Interpretation, StatisticalFemaleHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IILung NeoplasmsLymphocytesMaleMutagenicity TestsMutagensRisk FactorsSomatomedinsConceptsIGF-binding protein-3Lung cancer riskLung cancerCancer riskHigher IGFOdds ratioBPDE sensitivityInsulin-like growth factorMutagen sensitivityLevels of IGFPeripheral blood lymphocyte culturesLung cancer patientsSpecific histologic typesBleomycin sensitivityBlood lymphocyte culturesProliferation potentialHistologic typeTumor stageCancer patientsControl subjectsIGF-IIRisk factorsGenetic instabilityHumoral factorsLymphocyte culturesRelapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapseComparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy
Scorilas A, Yu H, Soosaipillai A, Gregorakis A, Diamandis E. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta 2000, 292: 127-138. PMID: 10686282, DOI: 10.1016/s0009-8981(99)00211-9.Peer-Reviewed Original ResearchConceptsPercent free PSAProstate cancer patientsFree PSAProstate cancerCancer patientsRadical prostatectomyPercent free prostate-specific antigen levelsCancer aggressivenessFree prostate specific antigen levelsProstate-specific antigen levelProstate cancer screening programsAge-matched menCancer screening programsRecurrent prostate cancerBenign prostatic hyperplasiaProstate cancer aggressivenessAntigen levelsTotal PSAGleason scoreHealthy menProstatic hyperplasiaProstatic diseaseScreening programPatientsPathological indicatorsClinical implications of prostate-specific antigen in men and women.
Yu H. Clinical implications of prostate-specific antigen in men and women. Journal Of Gender-Specific Medicine 2000, 3: 45-8, 53. PMID: 11253246.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPresence of PSAClinical implicationsLevels of PSABreast tissueBreast cancer patientsBreast cancer riskSex steroid hormonesValuable tumor markerExcess androgenFavorable prognosisPregnant womenBreast fluidCancer patientsNipple aspiratesProstate cancerClinical studiesCancer riskTumor markersCyst fluidFemale serumSteroid hormonesConcentration of PSAMore studiesWomen